Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


Novartis loses $21m franchise

Posted 3 August 2021 AM

Novartis has lost its stranglehold on the $21 million market for Jadenu, a treatment for chronic iron overload, with three generic competitors being listed on the PBS this month.

Cipla pharmaceuticals has listed Cipla Deferasirox, Alphapharm with Eferas and Pharmacor with Deferasirox FC.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Approvals Action
Melb pharma registers first copy
Long list of generic versions of PBS-listed drugs